[{"orgOrder":0,"company":"Advanced Accelerator Applications","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"FRANCE","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"Recombinant Annexin V-128","moa":"Annexin V","graph1":"Rheumatology","graph2":"Phase II","graph3":"Advanced Accelerator Applications","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Advanced Accelerator Applications \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Advanced Accelerator Applications \/ Undisclosed"},{"orgOrder":0,"company":"Nuon Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Tranilast","moa":"antiasthmatics\/antiallergics (not acting primarily as antihistamines)","graph1":"Rheumatology","graph2":"Phase II","graph3":"Nuon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Nuon Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Nuon Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Nuon Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Tranilast","moa":"antiasthmatics\/antiallergics (not acting primarily as antihistamines)","graph1":"Rheumatology","graph2":"Phase II","graph3":"Nuon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Nuon Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Nuon Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Adaptive Phage Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Bacteriophage","moa":"Bacteria","graph1":"Rheumatology","graph2":"Phase II","graph3":"Adaptive Phage Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adaptive Phage Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Adaptive Phage Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2025","type":"Inapplicable","leadProduct":"Methotrexate","moa":"Dihydrofolate reductase","graph1":"Rheumatology","graph2":"Phase II","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NYU Langone Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NYU Langone Health \/ Undisclosed"},{"orgOrder":0,"company":"Pharmos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Levotofisopam","moa":"GABR","graph1":"Rheumatology","graph2":"Phase II","graph3":"Pharmos","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharmos \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pharmos \/ Undisclosed"},{"orgOrder":0,"company":"Shanton Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"SAP-001","moa":"Glucose transporter type 9 (GLUT9)","graph1":"Rheumatology","graph2":"Phase II","graph3":"Shanton Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shanton Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Shanton Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Shanton Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"SAP-001","moa":"Glucose transporter type 9 (GLUT9)","graph1":"Rheumatology","graph2":"Phase II","graph3":"Shanton Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shanton Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Shanton Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Shanton Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"SAP-001","moa":"Glucose transporter type 9 (GLUT9)","graph1":"Rheumatology","graph2":"Phase II","graph3":"Shanton Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shanton Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Shanton Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Shanton Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"SAP-001","moa":"Glucose transporter type 9 (GLUT9)","graph1":"Rheumatology","graph2":"Phase II","graph3":"Shanton Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanton Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Shanton Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Shanton Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"SAP-001","moa":"Glucose transporter type 9 (GLUT9)","graph1":"Rheumatology","graph2":"Phase II","graph3":"Shanton Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanton Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Shanton Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"CANADA","productType":"Amino Acid","year":"2015","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Rheumatology","graph2":"Phase II","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Revive Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Revive Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"GeneScience Pharmaceuticals Co Ltd","sponsor":"Huashan Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Genakumab","moa":"IL-17A","graph1":"Rheumatology","graph2":"Phase II","graph3":"GeneScience Pharmaceuticals Co Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"GeneScience Pharmaceuticals Co Ltd \/ Huashan Hospital","highestDevelopmentStatusID":"8","companyTruncated":"GeneScience Pharmaceuticals Co Ltd \/ Huashan Hospital"},{"orgOrder":0,"company":"GeneScience Pharmaceuticals Co Ltd","sponsor":"Huashan Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Genakumab","moa":"IL-17A","graph1":"Rheumatology","graph2":"Phase II","graph3":"GeneScience Pharmaceuticals Co Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"GeneScience Pharmaceuticals Co Ltd \/ Huashan Hospital","highestDevelopmentStatusID":"8","companyTruncated":"GeneScience Pharmaceuticals Co Ltd \/ Huashan Hospital"},{"orgOrder":0,"company":"GeneScience Pharmaceuticals Co Ltd","sponsor":"Huashan Hospital | Hainan General Hospital | Linyi People's Hospital | The Second Affiliated Hospital of Chongqing Medical University | Changhai Hospital | The First Affiliated Hospital with Nanjing Medical University | Shengjing Hospital | Affiliated Hos","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Genakumab","moa":"IL-17A","graph1":"Rheumatology","graph2":"Phase II","graph3":"GeneScience Pharmaceuticals Co Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"GeneScience Pharmaceuticals Co Ltd \/ Huashan Hospital | Hainan General Hospital | Linyi People's Hospital | The Second Affiliated Hospital of Chongqing Medical University | Changhai Hospital | The First Affiliated Hospital with Nanjing Medical University | Shengjing Hospital | Affiliated Hos","highestDevelopmentStatusID":"8","companyTruncated":"GeneScience Pharmaceuticals Co Ltd \/ Huashan Hospital | Hainan General Hospital | Linyi People's Hospital | The Second Affiliated Hospital of Chongqing Medical University | Changhai Hospital | The First Affiliated Hospital with Nanjing Medical University | Shengjing Hospital | Affiliated Hos"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"SWEDEN","productType":"Protein","year":"2016","type":"Inapplicable","leadProduct":"Anakinra","moa":"Interleukin-1 receptor","graph1":"Rheumatology","graph2":"Phase II","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Swedish Orphan Biovitrum AB \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Swedish Orphan Biovitrum AB \/ Undisclosed"},{"orgOrder":0,"company":"TWi Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"TAIWAN","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Diacerein","moa":"JAK1\/TYK2","graph1":"Rheumatology","graph2":"Phase II","graph3":"TWi Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"TWi Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"TWi Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"TWi Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"TAIWAN","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Diacerein","moa":"JAK1\/TYK2","graph1":"Rheumatology","graph2":"Phase II","graph3":"TWi Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"TWi Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"TWi Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Osteal Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Antibiotic","year":"2018","type":"Inapplicable","leadProduct":"Vancomycin HCl","moa":"Peptidoglycan","graph1":"Rheumatology","graph2":"Phase II","graph3":"Osteal Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Osteal Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Osteal Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Osteal Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Vancomycin HCl","moa":"Peptidoglycan","graph1":"Rheumatology","graph2":"Phase II","graph3":"Osteal Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Osteal Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Osteal Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Dyve Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Colchicine","moa":"||pH","graph1":"Rheumatology","graph2":"Phase II","graph3":"Dyve Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Dyve Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Dyve Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"BCX4208","moa":"Purine nucleoside phosphorylase","graph1":"Rheumatology","graph2":"Phase II","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioCryst Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"BioCryst Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Ulodesine","moa":"Purine nucleoside phosphorylase","graph1":"Rheumatology","graph2":"Phase II","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioCryst Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"BioCryst Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Ulodesine","moa":"Purine nucleoside phosphorylase","graph1":"Rheumatology","graph2":"Phase II","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioCryst Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"BioCryst Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"R-Pharm","sponsor":"Covance | UNIMED Laboratories | Data Matrix Solutions | Center of Pharmaceutical Analytics LLC | OCT","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"RUSSIA","productType":"Protein","year":"2019","type":"Inapplicable","leadProduct":"RPH-104","moa":"receptor molecules","graph1":"Rheumatology","graph2":"Phase II","graph3":"R-Pharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"R-Pharm \/ Covance | UNIMED Laboratories | Data Matrix Solutions | Center of Pharmaceutical Analytics LLC | OCT","highestDevelopmentStatusID":"8","companyTruncated":"R-Pharm \/ Covance | UNIMED Laboratories | Data Matrix Solutions | Center of Pharmaceutical Analytics LLC | OCT"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Ardea Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"RDEA3170","moa":"Solute carrier family 22 member 12","graph1":"Rheumatology","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Ardea Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Ardea Biosciences"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Ardea Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"RDEA3170","moa":"Solute carrier family 22 member 12","graph1":"Rheumatology","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Ardea Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Ardea Biosciences"},{"orgOrder":0,"company":"Ardea Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"RDEA3170","moa":"Solute carrier family 22 member 12","graph1":"Rheumatology","graph2":"Phase II","graph3":"Ardea Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ardea Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ardea Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Ardea Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"RDEA3170","moa":"Solute carrier family 22 member 12","graph1":"Rheumatology","graph2":"Phase II","graph3":"Ardea Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ardea Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ardea Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Ardea Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"RDEA3170","moa":"Solute carrier family 22 member 12","graph1":"Rheumatology","graph2":"Phase II","graph3":"Ardea Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ardea Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ardea Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Ardea Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"RDEA3170","moa":"Solute carrier family 22 member 12","graph1":"Rheumatology","graph2":"Phase II","graph3":"Ardea Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ardea Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ardea Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Ardea Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"RDEA3170","moa":"Solute carrier family 22 member 12","graph1":"Rheumatology","graph2":"Phase II","graph3":"Ardea Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ardea Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ardea Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Ardea Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"RDEA3170","moa":"Solute carrier family 22 member 12","graph1":"Rheumatology","graph2":"Phase II","graph3":"Ardea Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ardea Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ardea Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Ardea Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"RDEA3170","moa":"Solute carrier family 22 member 12","graph1":"Rheumatology","graph2":"Phase II","graph3":"Ardea Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ardea Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ardea Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"CHINA","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"SHR4640","moa":"Solute carrier family 22 member 12","graph1":"Rheumatology","graph2":"Phase II","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"CHINA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"SHR4640","moa":"Solute carrier family 22 member 12","graph1":"Rheumatology","graph2":"Phase II","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"CHINA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"SHR4640","moa":"Solute carrier family 22 member 12","graph1":"Rheumatology","graph2":"Phase II","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"SHR4640","moa":"Solute carrier family 22 member 12","graph1":"Rheumatology","graph2":"Phase II","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"SHR4640","moa":"Solute carrier family 22 member 12","graph1":"Rheumatology","graph2":"Phase II","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Verinurad","moa":"Solute carrier family 22 member 12","graph1":"Rheumatology","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Contract Research Organization: USA | PAREXEL International Corporation | Clinical Laboratory | Harbor Hospital Laboratory | GenX Laboratories Inc. | Analytical Laboratory (Pharmacokinetic Sample Analysis) | Covance Bioanalytical Services","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Verinurad","moa":"Solute carrier family 22 member 12","graph1":"Rheumatology","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AstraZeneca \/ Contract Research Organization: USA | PAREXEL International Corporation | Clinical Laboratory | Harbor Hospital Laboratory | GenX Laboratories Inc. | Analytical Laboratory (Pharmacokinetic Sample Analysis) | Covance Bioanalytical Services","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Contract Research Organization: USA | PAREXEL International Corporation | Clinical Laboratory | Harbor Hospital Laboratory | GenX Laboratories Inc. | Analytical Laboratory (Pharmacokinetic Sample Analysis) | Covance Bioanalytical Services"},{"orgOrder":0,"company":"Ardea Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Verinurad","moa":"Solute carrier family 22 member 12","graph1":"Rheumatology","graph2":"Phase II","graph3":"Ardea Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ardea Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ardea Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Arhalofenate","moa":"Solute carrier family 22 member 12 | Peroxisome proliferator-activated receptor gamma","graph1":"Rheumatology","graph2":"Phase II","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Gilead Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Arhalofenate","moa":"Solute carrier family 22 member 12 | Peroxisome proliferator-activated receptor gamma","graph1":"Rheumatology","graph2":"Phase II","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Gilead Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Arhalofenate","moa":"Solute carrier family 22 member 12 | Peroxisome proliferator-activated receptor gamma","graph1":"Rheumatology","graph2":"Phase II","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Gilead Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Arhalofenate","moa":"Solute carrier family 22 member 12 | Peroxisome proliferator-activated receptor gamma","graph1":"Rheumatology","graph2":"Phase II","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gilead Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Gilead Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Arhalofenate","moa":"Solute carrier family 22 member 12 | Peroxisome proliferator-activated receptor gamma","graph1":"Rheumatology","graph2":"Phase II","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gilead Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Gilead Sciences \/ Undisclosed"},{"orgOrder":0,"company":"University of Leeds","sponsor":"Centocor","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Infliximab","moa":"TNF-alpha","graph1":"Rheumatology","graph2":"Phase II","graph3":"University of Leeds","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"University of Leeds \/ Centocor","highestDevelopmentStatusID":"8","companyTruncated":"University of Leeds \/ Centocor"},{"orgOrder":0,"company":"Atom Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"ABP-745","moa":"Undisclosed","graph1":"Rheumatology","graph2":"Phase II","graph3":"Atom Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Atom Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Atom Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"InventisBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"D-0120","moa":"Undisclosed","graph1":"Rheumatology","graph2":"Phase II","graph3":"InventisBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InventisBio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"InventisBio \/ Undisclosed"},{"orgOrder":0,"company":"InventisBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"D-0120","moa":"Undisclosed","graph1":"Rheumatology","graph2":"Phase II","graph3":"InventisBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InventisBio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"InventisBio \/ Undisclosed"},{"orgOrder":0,"company":"InventisBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"CHINA","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"D-0120","moa":"Undisclosed","graph1":"Rheumatology","graph2":"Phase II","graph3":"InventisBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InventisBio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"InventisBio \/ Undisclosed"},{"orgOrder":0,"company":"InventisBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"CHINA","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"D-0120","moa":"Undisclosed","graph1":"Rheumatology","graph2":"Phase II","graph3":"InventisBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InventisBio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"InventisBio \/ Undisclosed"},{"orgOrder":0,"company":"Dyve Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"DYV700","moa":"Undisclosed","graph1":"Rheumatology","graph2":"Phase II","graph3":"Dyve Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Lotion","sponsorNew":"Dyve Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Dyve Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Dyve Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"DYV-700","moa":"Undisclosed","graph1":"Rheumatology","graph2":"Phase II","graph3":"Dyve Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dyve Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Dyve Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Tianjin Tasly Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"CHINA","productType":"Plant Extract\/Herbal","year":"2019","type":"Inapplicable","leadProduct":"Jitongning","moa":"Undisclosed","graph1":"Rheumatology","graph2":"Phase II","graph3":"Tianjin Tasly Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tianjin Tasly Group \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Tianjin Tasly Group \/ Undisclosed"},{"orgOrder":0,"company":"Kissei Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"JAPAN","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"KUX-1151","moa":"Undisclosed","graph1":"Rheumatology","graph2":"Phase II","graph3":"Kissei Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kissei Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kissei Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Athera Biotechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Phosphorylcholine Human Monoclonal Antibody","moa":"Undisclosed","graph1":"Rheumatology","graph2":"Phase II","graph3":"Athera Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Athera Biotechnologies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Athera Biotechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Sunshine Guojian Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Recombinant Anti-IL-1 Humanized Monoclonal Antibody","moa":"Undisclosed","graph1":"Rheumatology","graph2":"Phase II","graph3":"Sunshine Guojian Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sunshine Guojian Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sunshine Guojian Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Selecta Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Enzyme","year":"2019","type":"Inapplicable","leadProduct":"SEL-212","moa":"Undisclosed","graph1":"Rheumatology","graph2":"Phase II","graph3":"Selecta Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Selecta Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Selecta Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Allena Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"ALLN-346","moa":"Urate","graph1":"Rheumatology","graph2":"Phase II","graph3":"Allena Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Allena Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Allena Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Allena Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"ALLN-346","moa":"Urate","graph1":"Rheumatology","graph2":"Phase II","graph3":"Allena Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Allena Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Allena Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Allena Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"ALLN-346","moa":"Urate","graph1":"Rheumatology","graph2":"Phase II","graph3":"Allena Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Allena Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Allena Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Allena Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"ALLN-346","moa":"Urate","graph1":"Rheumatology","graph2":"Phase II","graph3":"Allena Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Allena Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Allena Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Allena Pharmaceuticals","sponsor":"BDD Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"ALLN-346","moa":"Urate","graph1":"Rheumatology","graph2":"Phase II","graph3":"Allena Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Allena Pharmaceuticals \/ BDD Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Allena Pharmaceuticals \/ BDD Pharma"},{"orgOrder":0,"company":"Allena Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Engineered Urate Oxidase","moa":"Urate","graph1":"Rheumatology","graph2":"Phase II","graph3":"Allena Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Allena Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Allena Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Allena Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Engineered Urate Oxidase","moa":"Urate","graph1":"Rheumatology","graph2":"Phase II","graph3":"Allena Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Allena Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Allena Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"JW Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"URC102","moa":"Urate anion exchanger 1 (URAT1)","graph1":"Rheumatology","graph2":"Phase II","graph3":"JW Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"JW Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"JW Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"JW Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"URC102","moa":"Urate anion exchanger 1 (URAT1)","graph1":"Rheumatology","graph2":"Phase II","graph3":"JW Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"JW Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"JW Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Atom Bioscience & Pharmaceutical","sponsor":"Xicheng Jinrui Equity Investment Fund","pharmaFlowCategory":"D","therapeuticArea":"Rheumatology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Series C Financing","leadProduct":"Lingdolinurad","moa":"Urate transporter protein","graph1":"Rheumatology","graph2":"Phase II","graph3":"Jiangsu Atom Bioscience & Pharmaceutical","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rheumatology","amount2New":0.050000000000000003,"dosageForm":"Tablet","sponsorNew":"Jiangsu Atom Bioscience & Pharmaceutical \/ Xicheng Jinrui Equity Investment Fund","highestDevelopmentStatusID":"8","companyTruncated":"Jiangsu Atom Bioscience & Pharmaceutical \/ Xicheng Jinrui Equity Investment Fund"},{"orgOrder":0,"company":"Ampel BioSolutions","sponsor":"IND 2 Results","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Enzyme","year":"2015","type":"Inapplicable","leadProduct":"Pegloticase","moa":"Uric acid","graph1":"Rheumatology","graph2":"Phase II","graph3":"Ampel BioSolutions","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ampel BioSolutions \/ IND 2 Results","highestDevelopmentStatusID":"8","companyTruncated":"Ampel BioSolutions \/ IND 2 Results"},{"orgOrder":0,"company":"Selecta Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Enzyme","year":"2016","type":"Inapplicable","leadProduct":"SEL-037","moa":"Uric acid","graph1":"Rheumatology","graph2":"Phase II","graph3":"Selecta Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Selecta Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Selecta Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"JAPAN","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Febuxostat","moa":"Xanthine dehydrogenase","graph1":"Rheumatology","graph2":"Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"IBI128","moa":"Xanthine Dehydrogenase","graph1":"Rheumatology","graph2":"Phase II","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"JW Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rheumatology","graph2":"Phase II","graph3":"JW Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"JW Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"JW Pharmaceutical \/ Undisclosed"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
